Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EIK1005 Monotherapy and Combination With Pembrolizumab in Advanced Solid Tumors
NCT07262619Phase 2Recruiting
- Sponsor
- Eikon Therapeutics
- Start
- Jan 2026
- Primary completion
- Mar 2029
- Modality
- Small Molecules
- Countries
- 15
01
Overview
Phase 2, randomised, open-label trial of EIK1005 in solid tumor, gastric cancer (GC), colorectal cancer (CRC) and 2 more (3 arms), sponsored by Eikon Therapeutics. Primary endpoints: Dose-Limiting Toxicity at 21 days and Adverse Events. Started Jan 2026; status: recruiting.
02
Drugs
EIK1005
03
Conditions
solid tumorgastric cancer (GC)colorectal cancer (CRC)gastroesophageal junction cancerendometrial cancer (EC)
Beyond the preview
Go deeper on NCT07262619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07262619.